Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic

BACKGROUND: Many patients treated with Natalizumab experience wearing-off symptoms (WoS) towards the end of the administration cycle. During the pandemic we advised and asked patients undergoing treatment with Natalizumab if they wanted to be shifted from a standard interval dosing (StID of 4 weeks)...

Descripción completa

Detalles Bibliográficos
Autores principales: Magro, Giuseppe, Barone, Stefania, Tosto, Federico, De Martino, Antonio, Santange lo, Domenico, Manzo, Lucia, Pascarella, Angelo, Bruno, Pietro, Pasquale, Marilisa, Gambardella, Antonio, Valentino, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559546/
https://www.ncbi.nlm.nih.gov/pubmed/36229702
http://dx.doi.org/10.1007/s00415-022-11408-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559546/
https://www.ncbi.nlm.nih.gov/pubmed/36229702
http://dx.doi.org/10.1007/s00415-022-11408-0

Ejemplares similares